Premium
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials
Author(s) -
Woods William G.,
Franklin Anna R. K.,
Alonzo Todd A.,
Gerbing Robert B.,
Donohue Kathleen A.,
Othus Megan,
Horan John,
Appelbaum Frederick R.,
Estey Elihu H.,
Bloomfield Clara D.,
Larson Richard A.
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28344
Subject(s) - medicine , cog , cohort , young adult , myeloid leukemia , clinical trial , proportional hazards model , cohort study , log rank test , leukemia , survival analysis , oncology , artificial intelligence , computer science
BACKGROUND A retrospective meta‐analysis of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) was performed to determine if differences in outcome exist following treatment on pediatric versus adult oncology treatment regimens. METHODS Outcomes were compared of 517 AYAs with AML aged 16 to 21 years who were treated on Children's Oncology Group (COG), Cancer and Leukemia Group B (CALGB), and Southwest Oncology Group (SWOG) frontline AML trials from 1986 to 2008. RESULTS There was a significant age difference between AYA cohorts in the COG, CALGB, and SWOG trials (median, 17.2 versus 20.1 versus 19.8 years, P < .001). The 10‐year event‐free survival of the COG cohort was superior to the combined adult cohorts (38% ± 6% versus 23% ± 6%, log‐rank P = .006) as was overall survival (45% ± 6% versus 34% ± 7%), with a 10‐year estimate comparison of P = .026. However, the younger age of the COG cohort is confounding, with all patients aged 16 to 18 years doing better than those aged 19 to 21 years. Although the 10‐year relapse rate was lower for the COG patients (29% ± 6% versus 57% ± 8%, Gray's P < .001), this was offset by a higher postremission treatment‐related mortality of 26% ± 6% versus 12% ± 6% (Gray's P < .001). Significant improvements in 10‐year event‐free survival and overall survival were observed for the entire cohort in later studies. CONCLUSIONS Patients treated on pediatric trials had better outcomes than those treated on adult trials, but age is a major confounding variable, making it difficult to compare outcomes by cooperative group. Cancer 2013 ;119:4170–4179. © 2013 American Cancer Society .